SCHEMBL2322882

SCHEMBL2322882

CCOP(=O)(O)CC(=O)c1cc(C)ccc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
TSHR P16473 2/20 0.43
MAPT P10636 3/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 5/20 0.40
LMNA P02545 3/20 0.40
ALOX12 P18054 1/20 0.40
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.38
MITF O75030 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR1 P21453 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322311 0.88 SMN1; SMN2 (0.44) KMT2AMEN1MAPTTP53ALDH1A1
SCHEMBL1549244 0.82 KMT2A (0.48) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL2325155 0.77 TSHR (0.36) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL2329637 0.77 TDP1 (0.43) KMT2AMEN1TSHRMAPTTP53
SCHEMBL2322878 0.77 KMT2A (0.53) KMT2AMEN1TSHRMAPTTP53
SCHEMBL6490069 0.74 HPGD (0.51) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL27755241 0.74 KMT2A (0.53) KMT2AMEN1TSHRMAPTTP53
SCHEMBL2325440 0.73 NPC1 (0.50) KMT2AMAPTTP53MAPK1ALDH1A1
SCHEMBL9720686 0.73 MEN1 (0.65) KMT2AMEN1TSHRMAPTTP53
SCHEMBL31693367 0.73 MEN1 (0.65) KMT2AMEN1TSHRMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 KMT2A 2891/4885MEN1 1310/4885TSHR 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.